Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 4 , Pages 352-357 , July 2009

Dilemmas in the treatment of urothelial cancers of the prostate

Received 7 September 2007 ,Revised 13 December 2007 ,Accepted 13 December 2007.

References 

  1. Ende N, Woods LP, Shelley HS. Carcinoma originating in ducts surrounding the prostatic urethra. Am J Clin Pathol. 1963;40:183–189
  2. Pagano F, Bassi P, Ferrante GL, et al. Is stage pt4a (d1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? (A necessary distinction for contiguous or noncontiguous involvement). J Urol. 1996;155:244–247
  3. Esrig D, Freeman JA, Elmajian DA, et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol. 1996;156:1071–1076
  4. Njinou-Ngninkeu B, Lorge F, Moulin P, et al. Transitional cell carcinoma involving the prostate (A clinicopathological retrospective study of 76 cases). J Urol. 2003;169:149–152
  5. Volkmer BG, Kufer R, Maier S, et al. Outcome in patients with seminal vesicle invasion after radical cystectomy. J Urol. 2003;169:1299–1302
  6. Melicow MM, Hollowell JW. Intra-urothelial cancer (Carcinoma in situ, Bowen's disease of the urinary system: Discussion of thirty cases). J Urol. 1952;68:763–772
  7. Ortega LG, Whitmore WF, Murphy AI. In situ carcinoma of the prostate with intraepithelial extension into the urethra and bladder; Paget's disease of the urethra and bladder. Cancer. 1953;6:898–923
  8. Coutts AG, Grigor KM, Fowler JW. Urethral dysplasia and bladder cancer in cystectomy specimens. Br J Urol. 1985;57:535–541
  9. Herr HW, Donat SM. Prostatic tumor relapse in patients with superficial bladder tumors (15-Year outcome). J Urol. 1999;161:1854–1857
  10. Nixon RG, Chang SS, Lafleur BJ, et al. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol. 2002;167:502–505
  11. Reese JH, Freiha FS, Gelb AB, et al. Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J Urol. 1992;147:92–95
  12. Revelo MP, Cookson MS, Chang SS, et al. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies (Implications for possible apical sparing surgery). J Urol. 2004;171:646–651
  13. Schellhammer PF, Bean MA, Whitmore WF. Prostatic involvement by transitional cell carcinoma (Pathogenesis, patterns and prognosis). J Urol. 1977;118:399–403
  14. Wood DP, Montie JE, Pontes JE, et al. Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. J Urol. 1989;141:346–349
  15. Bates HR. Transitional cell carcinoma of the prostate. J Urol. 1969;101:206–207
  16. Rubenstein AB, Rubnitz ME. Transitional cell carcinoma of the prostate. Cancer. 1969;24:543–546
  17. Wolfe JH, Lloyd-Davies RW. The management of transitional cell carcinoma in the prostate. Br J Urol. 1981;53:253–257
  18. Seemayer TA, Knaack J, Thelmo WL, et al. Further observations on carcinoma in situ of the urinary bladder (Silent but extensive intraprostatic involvement). Cancer. 1975;36:514–520
  19. Grabstald H. Prostatic biopsy in selected patients with carcinoma in situ of the bladder (Preliminary report). J Urol. 1984;132:1117–1118
  20. Hardeman SW, Soloway MS. Urethral recurrence following radical cystectomy. J Urol. 1990;144:666–669
  21. Tongaonkar HB, Dalal AV, Kulkarni JN, et al. Urethral recurrences following radical cystectomy for invasive transitional cell carcinoma of the bladder. Br J Urol. 1993;72:910–914
  22. Kefer JC, Voelzke BB, Flanigan RC, et al. Risk assessment for occult malignancy in the prostate before radical cystectomy. Urology. 2005;66:1251–1255
  23. Bassi P. BCG (bacillus of Calmette-Guerin) therapy of high-risk superficial bladder cancer. Surg Oncol. 2002;11:77–83
  24. Davis JW, Sheth SI, Doviak MJ, et al. Superficial bladder carcinoma treated with bacillus Calmette-Guerin (Progression-free and disease specific survival with minimum 10-year follow-up). J Urol. 2002;167:494–500
  25. Rikken CH, van Helsdingen PJ, Kazzaz BA. Are biopsies from the prostatic urethra useful in patients with superficial bladder carcinoma?. Br J Urol. 1987;59:145–147
  26. Wood DP, Montie JE, Pontes JE, et al. Identification of transitional cell carcinoma of the prostate in bladder cancer patients (A prospective study). J Urol. 1989;142:83–85
  27. Donat SM, Wei DC, McGuire MS, et al. The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer. J Urol. 2001;165:1580–1584
  28. Hillyard RW, Ladaga L, Schellhammer PF. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra (Results of treatment with intravesical bacillus Calmette-Guérin). J Urol. 1988;139:290–293
  29. Schellhammer PF, Ladaga LE, Moriarty RP. Intravesical bacillus Calmette-Guérin for the treatment of superficial transitional cell carcinoma of the prostatic urethra in association with carcinoma of the bladder. J Urol. 1995;153:53–56
  30. Liedberg F, Chebil G, Mansson W. Urothelial carcinoma in the prostatic urethra and prostate (Current controversies). Expert Rev Anticancer Ther. 2007;7:383–390
  31. Canda AE, Tuzel E, Mungan MU, et al. Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder. Eur Urol. 2004;45:465–470
  32. LaFontaine PD, Middleman BR, Graham SD, et al. Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy. Urology. 1997;49:363–366
  33. Oates RD, Stilmant MM, Freedlund MC, et al. Granulomatous prostatitis following bacillus Calmette-Guérin immunotherapy of bladder cancer. J Urol. 1988;140:751–754
  34. Bretton PR, Herr HW, Whitmore WF, et al. Intravesical bacillus Calmette-Guérin therapy for in situ transitional cell carcinoma involving the prostatic urethra. J Urol. 1989;141:853–856
  35. Ovesen H, Poulsen AL, Steven K. Intravesical bacillus Calmette-Guérin with the Danish strain for treatment of carcinoma in situ of the bladder. Br J Urol. 1993;72:744–748
  36. Palou J, Xavier B, Laguna P, et al. In situ transitional cell carcinoma involvement of prostatic urethra (Bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate). Urology. 1996;47:482–484
  37. Orihuela E, Herr HW, Whitmore WF. Conservative treatment of superficial transitional cell carcinoma of prostatic urethra with intravesical BCG. Urology. 1989;34:231–237
  38. Palou Redorta J, Schatteman P, Huguet Perez J, et al. Intravesical instillations with bacillus Calmette-Guérin for the treatment of carcinoma in situ involving prostatic ducts. Eur Urol. 2006;49:834–838
  39. Shen SS, Lerner SP, Muezzinoglu B, et al. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006;37:726–734
  40. Leissner J, Ghoneim MA, Abol-Enein H, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer (Results of a prospective multicenter study). J Urol. 2004;171:139–144
  41. Lebret T, Herve JM, Barre P, et al. Urethral recurrence of transitional cell carcinoma of the bladder (Predictive value of preoperative latero-montanal biopsies and urethral frozen sections during prostatocystectomy). Eur Urol. 1998;33:170–174
  42. Stein JP, Clark P, Miranda G, et al. Urethral tumor recurrence following cystectomy and urinary diversion (Clinical and pathological characteristics in 768 male patients). J Urol. 2005;173:1163–1168
  43. Lin DW, Herr HW, Dalbagni G. Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy. J Urol. 2003;169:961–963
  44. Freeman JA, Tarter TA, Esrig D, et al. Urethral recurrence in patients with orthotopic ileal neobladders. J Urol. 1996;156:1615–1619
  45. Muto G, Bardari F, D'Urso L, et al. Seminal sparing cystectomy and ileocapsuloplasty (Long-term followup results). J Urol. 2004;172:76–80
  46. Vallancien G, Abou El Fettouh H, Cathelineau X, et al. Cystectomy with prostate sparing for bladder cancer in 100 patients (10-year experience). J Urol. 2002;168:2413–2417
  47. Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer (Treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer). Urology. 2007;69:62–79
  48. Montie JE, Wood DP, Mendendorp SV, et al. The significance and management of transitional cell carcinoma of the prostate. Semin Urol. 1990;8:262–268
  49. Solsona E, Iborra I, Ricos JV, et al. Recurrence of superficial bladder tumors in prostatic urethra. Eur Urol. 1991;19:93–96
  50. Schwalb DM, Herr HW, Fair WR. The management of clinically unconfirmed positive urinary cytology. J Urol. 1993;150:1751–1756

PII: S1078-1439(07)00331-6

doi: 10.1016/j.urolonc.2007.12.010

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 4 , Pages 352-357 , July 2009

Article Tools